Study shows that dosage of Amgen drug is higher in for-profit dialysis

A recent study showed that big for-profit dialysis chains give far higher doses of anemia drugs to their kidney patients than do nonprofit centers. The study found that for-profit dialysis chains may dose some patients with the Amgen drug at levels up to three times as high as nonprofit centers.

For the full article.

Lawyer Monthly - Legal Awards Winner
The National Trial Lawyers
Elder Care Matters Alliance
American Association for Justice
Fellow Litigation Counsel of America
Super Lawyers